Clinical Trials Logo

Clinical Trial Summary

To improve activities of daily living (ADL) and social functions is the important treatment plans and goals in participants with schizophrenia. Precise and effective measures of ADL and social functions are critical for clinicians to set up appropriate treatments plans, follow up participants' changes, and understand participants' progress. Three common measures of ADL and social functions used in participants with schizophrenia were the Comprehensive Occupational Therapy Evaluation Scale (COTES), the Activities of Daily Living Rating Scale third ed. (ADLRS-3), and the Social Functioning Scale. To investigators' knowledge, psychometric properties of these assessments have not been examined in participants with schizophrenia. Therefore, the purpose of the study is to (1) examine internal consistency and construct validity of these 3 assessments (the COTES, the ADLRS-3, and the Social Functioning Scale); and (2) calculate missing rate of self-report assessment (the ADLRS-3 and the Social Functioning Scale). Investigators expect that these results of internal consistency, construct validity and/or missing rate will provide empirical evidence for using these three measures in both clinical and research setting.


Clinical Trial Description

Social dysfunction is one of the main characteristics of participants with schizophrenia and influences participants' daily functions and quality of life. The Social Functioning Scale-Taiwan short form (SFST) is commonly used to measure social function in participants with schizophrenia. However, no study has examined psychometric properties of the SFST in participants with schizophrenia exclusively. Therefore, the study aimed to examine missing rate, ceiling effect/floor effect, internal consistency, and convergent validity of the SFST in participants with schizophrenia. Investigators obtained schizophrenic self-report data (the SFST and the ADLRS-3) from occupational therapy records. The Chinese version of the Activities of Daily Living Rating Scale (ADLRS-3), which has 10 domains, is commonly used for assessing activities of daily living (ADL) in participants with schizophrenia. However, construct validity (i.e., unidimensionality) for each domain of the ADLRS-3 is unknown, limiting the explanations of the test results. From occupational therapy records, investigators obtained self-report data of the ADLRS-3. Confirmatory factor analysis (CFA) was conducted to examine the 10 one-factor structures. If a domain showed an insufficient model fit, exploratory factor analysis (EFA) was performed to investigate the factor structure and choose one factor representing the original construct. Internal consistency was examined using Cronbach's alpha. Ceiling and floor effects were determined by the percentage of participants with the maximum and minimum scores in each domain, respectively. To evaluate construct validity (i.e., unidimensionality and convergent validity) and Rasch reliability of the Comprehensive Occupational Therapy Evaluation Scale (COTES) in participants with schizophrenia. From occupational therapy records, investigators collected COTES data of participants with schizophrenia. The 20-item COTES contains three subscales. For construct validity, investigators first examined the unidimensionality of each subscale using Rasch analysis. After unidimensionality was supported, investigators examined convergent validity using Pearson's r and Rasch reliability of the individual subscales in unidimensional and multidimensional approaches. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02930083
Study type Observational
Source Taipei City Hospital
Contact
Status Completed
Phase N/A
Start date October 2012
Completion date December 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A